Literature DB >> 8667047

Clinical significance of striatal DOPA decarboxylase activity in Parkinson's disease.

T Ishikawa1, V Dhawan, T Chaly, C Margouleff, W Robeson, J R Dahl, F Mandel, P Spetsieris, D Eidelberg.   

Abstract

UNLABELLED: We performed dynamic PET studies with fluorodopa (FDOPA) in 9 normal volunteers and 16 patients with Parkinson's disease to investigate the applicability of dopa decarboxylase (DDC) activity measurements as useful markers of the parkinsonian disease process.
METHODS: From the 3-O-methyl-FDOPA (3OMFD)/PET studies, we obtained mean population values of the kinetic rate constants for 3OMFD (K1M = 0.0400 and k2M = 0.0420). We applied these values to calculate striatal DDC activity using the FDOPA compartmental model. We estimated k3D in this group using dynamic FDOPA-PET and population mean K1M and k2M values. We then applied the mean population K1M and k2M values to estimate k3D(pop) to a new group (6 normal volunteers and 11 patients) studied only with dynamic FDOPA-PET. In all FDOPA/PET studies, we calculated striatal uptake rate constants (KiFD) using a graphical method and also measured the striato-occipital ratio (SOR).
RESULTS: Although DDC activity has been postulated as a precise indicator of presynaptic nigrostriatal dopaminergic function, KiFD and SOR provided better between-group discrimination than did estimates of striatal DDC activity. KiFD and k3D(pop) both correlated significantly with quantitative disease severity ratings, with a similar degree of accuracy (r = 0.69 and 0.63 for k3D(pop) and KiFD, respectively; p < 0.01).
CONCLUSION: Although estimated striatal DDC activity correlates with clinical disability, this measure is comparably less effective for early diagnosis. We conclude that a simple estimate such as striatal KiFD is superior to k3D measurements for most clinical and research applications.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8667047

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

2.  Brain (18)F-DOPA PET and cognition in de novo Parkinson's disease.

Authors:  Agnese Picco; Silvia Morbelli; Arnoldo Piccardo; Dario Arnaldi; Nicola Girtler; Andrea Brugnolo; Irene Bossert; Lucio Marinelli; Antonio Castaldi; Fabrizio De Carli; Claudio Campus; Giovanni Abbruzzese; Flavio Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-28       Impact factor: 9.236

3.  Pathophysiology of manganese-associated neurotoxicity.

Authors:  Brad A Racette; Michael Aschner; Tomas R Guilarte; Ulrike Dydak; Susan R Criswell; Wei Zheng
Journal:  Neurotoxicology       Date:  2011-12-21       Impact factor: 4.294

Review 4.  PET Imaging in Movement Disorders.

Authors:  Baijayanta Maiti; Joel S Perlmutter
Journal:  Semin Nucl Med       Date:  2018-08-16       Impact factor: 4.446

5.  Flow-metabolism dissociation in the pathogenesis of levodopa-induced dyskinesia.

Authors:  Vincent A Jourdain; Chris C Tang; Florian Holtbernd; Christian Dresel; Yoon Young Choi; Yilong Ma; Vijay Dhawan; David Eidelberg
Journal:  JCI Insight       Date:  2016-09-22

6.  Relationship of striatal dopamine synthesis capacity to age and cognition.

Authors:  Meredith N Braskie; Claire E Wilcox; Susan M Landau; James P O'Neil; Suzanne L Baker; Cindee M Madison; Jennifer T Kluth; William J Jagust
Journal:  J Neurosci       Date:  2008-12-24       Impact factor: 6.167

7.  Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease.

Authors:  Shigeki Hirano; Kotaro Asanuma; Yilong Ma; Chengke Tang; Andrew Feigin; Vijay Dhawan; Maren Carbon; David Eidelberg
Journal:  J Neurosci       Date:  2008-04-16       Impact factor: 6.167

8.  Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.

Authors:  S A Eshuis; P L Jager; R P Maguire; S Jonkman; R A Dierckx; K L Leenders
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-27       Impact factor: 9.236

9.  Orbitofrontal (18) F-DOPA Uptake and Movement Preparation in Parkinson's Disease.

Authors:  Lucio Marinelli; Arnoldo Piccardo; Laura Mori; Silvia Morbelli; Nicola Girtler; Antonio Castaldi; Agnese Picco; Carlo Trompetto; Maria Felice Ghilardi; Giovanni Abbruzzese; Flavio Nobili
Journal:  Parkinsons Dis       Date:  2015-06-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.